Tumor and Cancer-Targeted Exosome Modification Service
- Gene Engineering: Insertion of targeting ligands via membrane protein expression.
- Chemical Conjugation: Site-directed surface modification with ligands or antibodies.
- Use high-expressing parental cells to produce exosomes.
- Purify high-quality exosomes via ultracentrifugation combined with size exclusion chromatography (SEC).
- Gene Engineering Pathway: Construct gene vectors expressing targeting ligands.
- Chemical Conjugation Pathway: Employ click chemistry to conjugate tumor-targeting molecules to the exosome surface.
- Combine passive (self-assembly of hydrophobic drugs) and active (electroporation, sonication) loading methods to maximize encapsulation efficiency.
- Validate drug loading rates and release kinetics.
- Size and concentration analysis via NTA, marker protein detection (CD63/TSG101).
- In vitro targeting assessment (tumor cell binding), in vivo biodistribution tracking (fluorescence imaging).
- Efficacy evaluation (cytotoxicity assays, tumor inhibition rate, safety testing).
Exosomes are nano-sized (30–150 nm) extracellular vesicles actively secreted by cells, carrying a rich cargo of proteins, nucleic acids, and lipids derived from their parent cells. Naturally involved in intercellular communication and molecular transport, exosomes have emerged as next-generation "intelligent drug delivery carriers" due to their unique biological advantages—low immunogenicity, high-efficiency barrier penetration (e.g., crossing the blood–brain barrier or tumor stroma), and prolonged drug circulation half-life. Their phospholipid bilayer structure enables the encapsulation of diverse therapeutic agents—including chemotherapeutics, nucleic acids, and proteins—protecting payloads from degradation while ensuring precise accumulation at target sites. This significantly enhances therapeutic efficacy while minimizing systemic toxicity.
Chen, L. et al. Front Cell Dev Biol. 2022.
Figure 1. The Utilization of Genetically Engineered MSCs-Derived Exosomes as Drug Carriers
In contrast to traditional chemotherapy and synthetic nanocarriers, which often face limitations such as non-specific distribution, high immune clearance, and poor biocompatibility, exosomes offer a promising alternative for targeted cancer therapy. Tumor-derived exosomes possess natural homing capabilities, preferentially migrating to primary or metastatic tumor sites. Their high programmability allows for engineered modifications that confer “active targeting” functionality. For instance, gene engineering enables the parental cells to express tumor-specific ligands (e.g., antibodies or peptides), resulting in surface-displayed targeting moieties on secreted exosomes. Alternatively, chemical conjugation strategies such as click chemistry or hydrophobic insertion can be used to anchor targeting molecules (e.g., folic acid or aptamers) onto the exosome membrane. These strategies greatly enhance targeting specificity and enrichment efficiency and can be combined with controlled release designs to enable a new paradigm of “precise delivery–controlled drug release–synergistic tumor killing” in cancer therapy.
He, J. et al. Drug Deliv Transl Res. 2022.
Figure 2. Exosome Engineering for Targeted Tumor Drug Delivery
Services at MtoZ Biolabs
MtoZ Biolabs specializes in customized Tumor and Cancer-Targeted Exosome Modification Service for research institutions and pharmaceutical companies. We are dedicated to developing efficient and safe exosome-based drug delivery systems through molecular modification and functional enhancement. By leveraging advanced gene engineering and chemical conjugation technologies, we have built a delivery platform that integrates targeting capability, drug loading efficiency, and low toxicity—empowering our clients to overcome drug delivery challenges and accelerate the clinical translation of anti-cancer therapies. Our service include, but are not limited to:
1. Exosome Isolation and Preparation
Production from various cell sources including stem cells, immune cells, or customer-designated cell lines.
2. Targeting Engineering and Modification
3. Therapeutic Drug Loading
Custom drug loading processes for small molecules, nucleic acids, and protein therapeutics.
4. In Vitro / In Vivo Functional Validation
Evaluation of targeting specificity, efficacy, and safety.
5. Scale-up Support
From lab-scale to pilot-scale process development to support preclinical research.
Analysis Workflow
1. Targeting Needs Assessment
Design optimal modification strategies based on cancer type, therapeutic targets, and drug characteristics (e.g., chemotherapeutic agents, nucleic acids, proteins).
2. Exosome Production and Isolation
3. Functional Modification
4. Drug Loading and Optimization
5. Quality Control and Functional Verification
Service Advantages
1. Advanced Targeting Technologies: Integration of gene engineering and chemical conjugation enables flexible adaptation to diverse therapeutic scenarios.
2. Fully Customized Workflow: Tailored solutions from cell source selection to final product delivery.
3. Rigorous Quality Control: Exosome purification and validation processes based on ISO standards ensure batch-to-batch consistency.
4. Cost-Effective Delivery: Optimized production workflows to reduce R&D time and costs.
5. Regulatory Compliance Support :GLP-compliant processes to facilitate rapid IND application and clinical development.
Applications
1. Precision Drug Delivery: Enhances local drug concentration in tumor tissues while minimizing systemic exposure and off-target toxicity.
2. Combination Therapy: Synergizes with chemotherapy, gene editing, or immunoactivation to boost anti-cancer efficacy.
3. Overcoming Drug Resistance: Bypasses drug efflux mechanisms via membrane-mediated delivery to restore therapeutic sensitivity.
Precision oncology demands highly efficient and safe delivery platforms. Backed by extensive experience in exosome engineering, MtoZ Biolabs provides end-to-end solutions from targeting design to preclinical validation—helping clients overcome the limitations of conventional therapies and accelerate the development of innovative anti-cancer drugs. Partner with MtoZ Biolabs for technical expertise, reliable delivery, and efficient clinical translation. Whether for fundamental research or drug development, we are ready to work with you to unlock the full potential of exosome-based targeted delivery technologies.
How to order?
